This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Cookies Policy.

This page is intended for US healthcare providers only.

This page is intended for US healthcare providers only.

IN LATER LINES OF THERAPY, REGIMEN TOLERABILITY BECOMES INCREASINGLY IMPORTANT1-3

Nonspecific inhibition of the HER family may lead to an increase in overall treatment-related toxicity.4-5

  • Inhibition of EGFR has been associated with side effects, such as diarrhea and rash

Selective targeting of HER2 may reduce the risk of off-target toxicities.4,5

Explore the HER2 opportunity in mCRC

Seagen: Advancing science to transform treatment of HER2+ cancer

EGFR = epidermal growth factor receptor; HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer.

References: 1. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8(6):514-520. 2. Siebenhüner A, De Dosso S, Meisel A, Wagner AD, Borner M. Metastatic colorectal carcinoma after second progression and the role of trifluridine-tipiracil (TAS-102) in Switzerland. Oncol Res Treat. 2020;43(5):237-244. 3. Gresham G, Diniz MA, Razaee ZS, et al. Evaluating treatment tolerability in cancer clinical trials using the toxicity index. J Natl Cancer Inst. 2020;112(12):1266-1274. 4. Li J. Diarrhea with HER2-targeted agents in cancer patients: a systematic review and meta-analysis. J Clin Pharmacol. 2019;59(7):935-946. 5. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486.

Seagen and are US registered trademarks of Seagen Inc.

© 2022 Seagen Inc., Bothell, WA 98021.
All rights reserved. US-DIS-22-272-MT Produced in USAProduced in USA